The KAUST Pathogen Genomics Laboratory (PGL), led by Professor Arnab Pain, is using DNA and RNA sequencing to study the SARS-CoV-2 virus. The lab is part of KAUST's Rapid Research Response Team (R3T), supporting Saudi healthcare stakeholders in combating COVID-19. Pain and his Ph.D. student Sharif Hala are partnering with the Saudi-CDC and Ministry of Health hospitals to sequence Saudi SARS-CoV-2 samples. Why it matters: This effort provides crucial data for understanding and monitoring the virus's spread and evolution within the Kingdom, informing public health strategies.
KAUST researchers have developed a CRISPR-Cas system using a heat-stable Cas13 protein (TccCas13a) from Thermoclostridium caenicola, compatible with RT-LAMP for rapid viral detection. The new assay, named OPTIMA-dx, enhances the specificity of RT-LAMP tests by reducing false positives in SARS-CoV-2 detection. The team, led by Dr. Magdy Mahfouz and doctoral student Ahmed Mahas, is transitioning the product to a startup phase for commercialization. Why it matters: This innovation could significantly improve point-of-care diagnostics for COVID-19 and other infections by providing a more accurate and easier-to-use testing method.
A KAUST-led team developed NIRVANA, a portable, briefcase-sized device for rapid detection and sequencing of SARS-CoV-2, influenza, and other viruses. The test utilizes isothermal recombinase amplification (RPA) and was validated on clinical samples and wastewater. NIRVANA can differentiate SARS-CoV-2 strains and doesn't require expensive infrastructure. Why it matters: This innovation enables rapid, decentralized virus detection and surveillance, crucial for pandemic response and monitoring new variants across the region.
KAUST researchers are developing iSCAN, a rapid, field-deployable COVID-19 test using RT-LAMP coupled with CRISPR-Cas12. The iSCAN system is designed for rapid, specific detection of SARS-CoV-2 and can be deployed by untrained personnel. The researchers are benchmarking iSCAN against commercial kits and seeking emergency use authorization from the Saudi FDA. Why it matters: A rapid, accurate, and field-deployable COVID-19 test could significantly improve pandemic management and control in Saudi Arabia and beyond.
KAUST researchers are analyzing the SARS-CoV-2 genome to identify potential targets for treatment and vaccine development. They are using the KAUST Metagenome Analysis Platform (KMAP) and the university's supercomputer to compare and analyze genomic data. The research focuses on identifying key genes for detection and treatment of COVID-19. Why it matters: This research contributes to the global effort to combat the pandemic and highlights KAUST's capabilities in genomic data analysis and computational bioscience.
KAUST's Computational Bioscience Research Center (CBRC) and King Abdulaziz City for Science and Technology (KACST) have collaborated on research into methicillin-resistant Staphylococcus aureus (MRSA) within Saudi Arabia, starting in July 2018. The two-year project aims to understand MRSA drug resistance mechanisms specific to the Kingdom and its regions, with the goal of developing public health strategies. The project involves sequencing samples and performing bioinformatics analysis to support a network of researchers in the country. Why it matters: This initiative enhances Saudi Arabia's capacity to predict, prevent, and control infectious diseases, aligning with national health objectives and building local expertise in computational bioscience.
A KAUST Rapid Research Response Team (R3T) is collaborating with healthcare stakeholders to combat COVID-19. Xin Gao and his Structural and Functional Bioinformatics (SFB) Group are developing an AI-based diagnosis pipeline from CT scans of COVID-19 patients. The AI pipeline aims to address the high false negative rates associated with nucleic acid detection. Why it matters: This research could improve COVID-19 diagnostics and potentially inform understanding of viral pathogenesis.
KAUST and King Faisal Specialist Hospital and Research Centre (KFSH&RC) are collaborating to develop bioelectronic sensors for rapid pathogen detection. These sensors aim to provide cheap and accurate results, potentially replacing conventional lab tests. A COVID-19 saliva test developed by KAUST researchers showed comparable sensitivity to PCR tests with a 15-minute turnaround. Why it matters: This partnership accelerates the development of novel diagnostic tools, which could improve healthcare accessibility in remote areas and low-income countries within the region.